Cariprazine

Gedeon Richter: Cariprazine shows effectiveness in the treatment for dual disorder

Retrieved on: 
Monday, April 15, 2024
Crave, Disorder, Congress, European Psychiatric Association, Gedeon Richter, Poster, DSM-IV codes, Cariprazine, Science, Patient, Scott Richter, Observational study, Medical diagnosis, Caregiver, Anxiety, Mood, Pharmaceutical industry

The scientific posters proved that cariprazine might be an appropriate treatment not only for early and late-stage schizophrenia, but also for the difficult-to-treat dual disorder (schizophrenia and comorbid substance use disorder).

Key Points: 
  • The scientific posters proved that cariprazine might be an appropriate treatment not only for early and late-stage schizophrenia, but also for the difficult-to-treat dual disorder (schizophrenia and comorbid substance use disorder).
  • Furthermore, a new transdiagnostic tool for quantifying, and visualizing symptom severity and functional disability of patients with different psychiatric conditions was presented.
  • A special Gedeon Richter publication, the "Candid Book" was also introduced by the authors, which contains useful, everyday suggestions for the caregivers of patients.
  • The final poster was providing information on the potential of cariprazine in dual disorder, the co-occurrence of a major psychiatric disorder and comorbid substance use disorder.

Gedeon Richter: an effective treatment for female schizophrenia patients

Retrieved on: 
Wednesday, October 18, 2023
Cariprazine, Hallucination, Scott Richter, Physician, Asociality, Observational study, Alogia, Patient, ECNP, Gideon, Delusion, Anhedonia, European College of Neuropsychopharmacology, Risperidone, Woman, Pharmaceutical industry, Schizophrenia

Cariprazine was found to be effective in women with schizophrenia in a real-life setting with around 70% of the physicians being satisfied with the results.

Key Points: 
  • Cariprazine was found to be effective in women with schizophrenia in a real-life setting with around 70% of the physicians being satisfied with the results.
  • Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting about 1% of the population.
  • Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
  • Treatment with risperidone is still one of the most used standards when it comes to schizophrenia.

Gedeon Richter: A new hope for treatment-resistant schizophrenia?

Retrieved on: 
Thursday, October 5, 2023
Scott Richter, Congress, Safety, Cariprazine, Clozapine, World Psychiatric Association, TRS, Gedeon Richter (company), Gedeon Richter, Patient, Pharmaceutical industry, Schizophrenia, Psychiatry

Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.

Key Points: 
  • Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.
  • Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
  • Cariprazine is a 3rd generation antipsychotic medication with a unique receptor profile and proven efficacy in persistent negative symptoms.
  • At the Gedeon Richter and Recordati supported Meet-the-Expert session, Professor Christoph U. Correll talked about the activating-sedating effects of antipsychotics with special focus on cariprazine.

Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

Retrieved on: 
Monday, May 22, 2023
Volunteering, Human, Central nervous system, Metabolism, Schizophrenia, American Society for Pharmacology and Experimental Therapeutics, New Drug Application, PME, NDA, CYP3A, Schizoaffective disorder, SAD, Cmax, Experiment, CNS, Clozapine, CYP3A4, Risperidone, Plasma, Aripiprazole, Animal, DSM-IV codes, Patient, Phenytoin, Itraconazole, Mouse, State, Glucuronic acid, Pharmacology, Lurasidone, Society, Brexpiprazole, Cariprazine, Safety, ASPET, Vaccine, Pharmaceutical industry, Brilaroxazine

CUPERTINO, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented two posters on promising clinical pharmacology and safety studies data on the novel serotonin-dopamine stabilizer brilaroxazine at the American Society for Pharmacology and Experimental Therapeutics (ASPET) 2023 annual meeting took place in St. Louis, Missouri, USA, May 18-21, 2023. The ASPET posters are available at revivapharma.com/publications. Brilaroxazine is currently in phase 3 clinical trials for schizophrenia and topline data from the pivotal phase 3 is anticipated in mid this year.

Key Points: 
  • Brilaroxazine is currently in phase 3 clinical trials for schizophrenia and topline data from the pivotal phase 3 is anticipated in mid this year.
  • “These data support the concomitant use of brilaroxazine with other medications metabolized by CYP3A4 as most schizophrenia patients take multiple concomitant medications.
  • As part of the required clinical studies for New Drug Application (NDA), the drug-drug interactions between brilaroxazine with a strong CYP3A4 inhibitor (itraconazole) and inducer (phenytoin) were evaluated.
  • Brilaroxazine single dose co-administered with phenytoin at steady-state resulted in decrease of ~33%, 57% and 54% in brilaroxazine Cmax, AUC0-t, and AUC0∞, respectively.

VRAYLAR Now Reimbursed by the Province of Quebec for Schizophrenia

Retrieved on: 
Monday, May 1, 2023
Hallucination, Employment, FRCP, Education, Chợ Rã, Delusion, Emotion, Patient, SSC, Physician, Cariprazine, RAMQ, DSM-IV codes, Health Canada, Residential care, Health insurance, Nursing, MD, Schizophrenia

Winnipeg, Manitoba--(Newsfile Corp. - May 1, 2023) - VRAYLAR (cariprazine) for the treatment of Schizophrenia in adults has received exception medication status on the list of medications in the province of Quebec.

Key Points: 
  • Winnipeg, Manitoba--(Newsfile Corp. - May 1, 2023) - VRAYLAR (cariprazine) for the treatment of Schizophrenia in adults has received exception medication status on the list of medications in the province of Quebec.
  • This decision will make the drug more accessible, significantly improving the lives of individuals and families affected by Schizophrenia in Quebec.
  • "VRAYLAR (cariprazine) can be life-changing for adults living with Schizophrenia because it's the first drug of its kind made specifically to target symptoms," says Chris Summerville, CEO of the Schizophrenia Society of Canada.
  • "This decision means that patients in Quebec with schizophrenia will have access to more effective treatment options."

Gedeon Richter: Cariprazine demonstrates broad-spectrum antidepressant effects across different patient populations

Retrieved on: 
Wednesday, March 29, 2023
Depression, Depression (mood), Observational study, Hospital, Suicide, Clinical trial, Quality of life, EPA, Plasma, Scott Richter, DSM-IV codes, Patient, Risk, Grammatical mood, Diagnosis, Poster, Knowledge, European Psychiatric Association, Cariprazine, Bipolar disorder, Total, Pharmaceutical industry, TRR, Schizophrenia

Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.

Key Points: 
  • Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and mood symptoms, affecting 1% of the population.
  • Although antipsychotics are effective in the treatment of positive symptoms, the management of negative, cognitive, and affective symptoms often remains challenging.
  • Another poster highlighted the increasing need for gathering real-world data in order to understand how the drug works in heterogeneous patient populations, therefore complementing the knowledge gained from clinical trials.
  • The 3rd poster provided details on the examination of the therapeutic reference range (TRR) for cariprazine 1.5 mg/day to 6 mg/day in schizophrenia studies.

The Global Antipsychotic Drugs Market to Register Growth at a CAGR of ~7% by 2027 | DelveInsight

Retrieved on: 
Thursday, February 2, 2023
Pharmacy, Personality disorder, Pfizer, PTSD, Schizoaffective disorder, Safety, Sun Pharma, Lundbeck, Ethics, Cariprazine, Statistics, Anxiety, Alvogen, Bristol Myers Squibb, HDEC, Mental disorder, Bipolar I disorder, Disorder, Depression, Post-traumatic stress disorder, Food, Hallucination, DSM-IV codes, Zydus Lifesciences, Prevalence, USFDA, US Foods, LAS, Mental health, GSK, Laboratory, Government, MDMA, Thought, Addiction, USP, Schizophrenia, Sale, Bipolar disorder, Research, Agonist, Silvio Pettirossi International Airport, COVID-19, Bayer, GSK plc, Cardinal Health, World Health Organization, Drug development, Mania, WHO, Viatris, Conduct disorder, AbbVie, Delusion, Pharmaceutical industry, Medsafe

LAS VEGAS, Feb. 2, 2023 /PRNewswire/ -- DelveInsight's Antipsychotic Drugs Market Insights report provides the current and forecast market analysis, individual leading antipsychotic drugs companies' market shares, challenges, antipsychotic drugs market drivers, barriers, and trends, and key antipsychotic drugs companies in the market.

Key Points: 
  • LAS VEGAS, Feb. 2, 2023 /PRNewswire/ -- DelveInsight's Antipsychotic Drugs Market Insights report provides the current and forecast market analysis, individual leading antipsychotic drugs companies' market shares, challenges, antipsychotic drugs market drivers, barriers, and trends, and key antipsychotic drugs companies in the market.
  • As per DelveInsight estimates, North America is anticipated to dominate the global antipsychotic drugs market during the forecast period.
  • Furthermore, increased awareness resulted in increased adoption of these drugs in key countries, significantly increasing antipsychotic drugs market growth in key countries.
  • However, the high cost of drug development and launch, addiction caused by antipsychotic drugs, and the stringent regulatory approval process may stall the antipsychotic drugs market growth.

Gedeon Richter: The incidence of side effects decreased over time with cariprazine

Retrieved on: 
Tuesday, October 18, 2022
Akathisia, Time, Birth, Female, ECNP, Woman, Schizophrenia, European College of Neuropsychopharmacology, Patient, Gedeon Richter, Industry, Polypharmacy, Cariprazine, Lists of diseases, Incidence, Product, Clinical trial, Scott Richter, Pharmaceutical industry

Issues regarding polypharmacy, and the special needs of women with schizophrenia were also highlighted in an industry-sponsored product theater and satellite symposium.

Key Points: 
  • Issues regarding polypharmacy, and the special needs of women with schizophrenia were also highlighted in an industry-sponsored product theater and satellite symposium.
  • One of the poster presentations at ECNP authored by Professor Christoph U. Correll highlighted that the incidence of adverse drug reactions with cariprazine decreases over time.
  • Furthermore, higher doses of cariprazine do not seem to increase neither rescue medication use nor extrapyramidal-related symptoms such as akathisia.
  • Compared to previous treatment, patients with schizophrenia needed less rescue medications with cariprazine and experienced fewer side effects.

Major Depressive Disorder Market Research Report 2022: Insight, Epidemiology and Market Forecast 2019-2032 - Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022
Pharmaceutical, Health, Mental Health, CNS, US FDA, Lists of diseases, Population, Manic, LY03005, Therapy, Attention, Schizophrenia, Comprehension, Technology, SAGE, AbbVie, Cariprazine, NMDA, Bupropion, Electroconvulsive therapy, Gaps, Clinical trial, Physician, ECT, News, Lists of people executed in the United States, Pharmacodynamics, Psychotherapy, Dextromethorphan, Norepinephrine, D3, Patient, Adult, SME, Disorder, Major depressive disorder, D2, MDD, Bipolar I disorder, Pharmaceutical industry, Medical device, Epidemiology

The "Major Depressive Disorder - Market Insight, Epidemiology And Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Major Depressive Disorder - Market Insight, Epidemiology And Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Major Depressive Disorder (MDD) - Market Insights, Epidemiology, and Market Forecast - 2032' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of major depressive disorder (MDD) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • The drug chapter segment of the major depressive disorder (MDD) report encloses the detailed analysis of major depressive disorder (MDD) marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs.
  • Their opinion helps understand and validate current and emerging therapy treatment patterns or major depressive disorder (MDD) market trends.

Gedeon Richter: Benzodiazepines had no additive effects to cariprazine's efficacy, neither on total symptoms, nor on hostility; cariprazine with and without benzodiazepine was significantly better than corresponding placebo in improving acute schizophreni

Retrieved on: 
Friday, June 10, 2022
PNS, Benzodiazepine, EPA, Prognosis, Scott Richter, Positive, Hostility, Cariprazine, Positive and Negative Syndrome Scale, Patient, Poster, Grammatical mood, MADRS, Population, Lists of diseases, Risperidone, European Psychiatric Association, Residential care, Pharmaceutical industry, Schizophrenia

In the oral communication by Professor Christoph U. Correll, it was shown that benzodiazepines had no additive effects to cariprazine's efficacy, neither on total symptoms, nor on hostility.

Key Points: 
  • In the oral communication by Professor Christoph U. Correll, it was shown that benzodiazepines had no additive effects to cariprazine's efficacy, neither on total symptoms, nor on hostility.
  • Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, cognitive, and affective symptoms, affecting 1% of the population.
  • In addition, cariprazine without benzodiazepines significantly outperformed corresponding placebo in improving hostility symptoms.
  • Patients from schizophrenia and bipolar depression studies were included in the analyses investigating cariprazine's potential in improving depressive symptoms.